Spongean alkaloids protect rat kidney cells against cisplatin-induced cytotoxicity

Anti-Cancer Drugs

Volumn 25, Issue 8, 2014, Pages 917-929

  Funk, Florian ^a   Krüger, Katharina ^a   Henninger, Christian ^a   Wätjen, Wim ^a   Proksch, Peter ^b   Thomale, Jürgen ^c   Fritz, Gerhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Institute of Pharmaceutical Biology   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

aaptamine; cisplatin; natural compounds; nephrotoxicity; normal tissue damage

Indexed keywords

AAPTAMINE; AEROPLYSININ 1; ALKALOID DERIVATIVE; ANTHRACYCLINE DERIVATIVE; CHECKPOINT KINASE 1; CISPLATIN; DOXORUBICIN; HARPAGOSIDE; HISTONE H2AX; OXALIPLATIN; PROTEIN P53; UNCLASSIFIED DRUG; ACETONITRILE DERIVATIVE; AEROPLYSININ I; ALKALOID; ANTINEOPLASTIC AGENT; CYCLOHEXENE DERIVATIVE; H2AFX PROTEIN, HUMAN; HISTONE; NAPHTHYRIDINE DERIVATIVE; PLANT EXTRACT; PLATINUM COMPLEX;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENCY; ENDOTHELIUM CELL; GENOTOXICITY; HUMAN; HUMAN CELL; KIDNEY TUBULE DAMAGE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; SPONGE (PORIFERA); ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; GLOMERULUS; ISOLATION AND PURIFICATION; KIDNEY TUBULE; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PODOCYTE; TUMOR CELL LINE;

ACETONITRILES; ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CISPLATIN; CYCLOHEXENES; CYTOPROTECTION; DNA DAMAGE; DRUG INTERACTIONS; HISTONES; HUMANS; KIDNEY GLOMERULUS; KIDNEY NEOPLASMS; KIDNEY TUBULES; NAPHTHYRIDINES; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PLANT EXTRACTS; PODOCYTES; PORIFERA; RATS;

EID: 84905459613     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000119     Document Type: Article

References (47)

1. Ali I, Wani WA, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy. Anticancer Agents Med Chem 2013; 13:296-306.
2. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334:115-124.
3. Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 2008; 15:2656-2663.
4. Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806: 172-182.
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-7279.
6. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005; 53:3-11.
7. Roos WP, Kaina B. DNA damage-induced apoptosis: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2013; 332:237-248.
8. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23:460-464.
9. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-1883.
10. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23.
11. Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, et al. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 2007; 73:1499-1510.
12. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008; 283:6572-6583.
13. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86:396-402.
14. Yonezawa A, Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 2011; 81:563-568.
15. Lee S, Moon SO, Kim W, Sung MJ, Kim DH, Kang KP, et al. Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury. Nephrol Dial Transplant 2006; 21:2085-2095.
16. Khan SA, Priyamvada S, Khan W, Khan S, Farooq N, Yusufi AN. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol Res 2009; 60:382-391.
17. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatininduced nephrotoxicity. J Pharmacol Exp Ther 2010; 335:2-12.
18. Mohan A, Narayanan S, Sethuraman S, Krishnan UM. Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy. Anticancer Agents Med Chem 2013; 13:281-295.
19. Spatafora C, Tringali C. Natural-derived polyphenols as potential anticancer agents. Anticancer Agents Med Chem 2012; 12:902-918.
20. Hadi SM, Bhat SH, Azmi AS, Hanif S, Shamim U, Ullah MF. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin Cancer Biol 2007; 17:370-376.
21. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43 (Suppl):S61-S68.
22. Shao Rong G, Cao Chun X, Zhang H, Kohn Kurt W, Wold Marc S, Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J 1999; 18:1397-1406.
23. Bracke ME, Vanhoecke BW, Derycke L, Bolca S, Possemiers S, Heyerick A, et al. Plant polyphenolics as anti-invasive cancer agents. Anticancer Agents Med Chem 2008; 8:171-185.
24. Thakur VS, Gupta K, Gupta S. The chemopreventive and chemotherapeutic potentials of tea polyphenols. Curr Pharm Biotechnol 2012; 13:191-199.
25. Lee AH, Fraser ML, Meng X, Binns CW. Protective effects of green tea against prostate cancer. Expert Rev Anticancer Ther 2006; 6:507-513.
26. Heiss C, Keen CL, Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J 2010; 31:2583-2592.
27. Liedert B, Pluim D, Schellens J, Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 2006; 34:e47.
28. Bara R, Zerfass I, Aly AH, Goldbach-Gecke H, Raghavan V, Sass P, et al. Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus. J Med Chem 2013; 56:3257-3272.
29. Ebel R, Brenzinger M, Kunze A, Gross HJ, Proksch P. Wound activation of protoxins in the marine sponge Aplysina aerophoba. J Chem Ecol 1997; 23:1451-1462.
30. Hertiani T, Edrada-Ebel R, Ortlepp S, van Soest RW, de Voogd NJ, Wray V, et al. From anti-fouling to biofilm inhibition: new cytotoxic secondary metabolites from two Indonesian Agelas sponges. Bioorg Med Chem 2010; 18:1297-1311.
31. Pham CD, Hartmann R, Muller WE, de Voogd N, Lai D, Proksch P. Aaptamine derivatives from the Indonesian sponge Aaptos suberitoides. J Nat Prod 2013; 76:103-106.
32. Olive PL. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 2004; 75:355-373.
33. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
34. Kreuter MH, Leake RE, Rinaldi F, Muller-Klieser W, Maidhof A, Muller WE, Schroder HC. Inhibition of intrinsic protein tyrosine kinase activity of EGFreceptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)-aeroplysinin-1. Comp Biochem Physiol B 1990; 97:151-158.
35. Martinez-Poveda B, Garcia-Vilas JA, Cardenas C, Melgarejo E, Quesada AR, Medina MA. The brominated compound aeroplysinin-1 inhibits proliferation and the expression of key pro-inflammatory molecules in human endothelial and monocyte cells. PLoS One 2013; 8:e55203.
36. Martinez-Poveda B, Rodriguez-Nieto S, Garcia-Caballero M, Medina MA, Quesada AR. The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway. Mar Drugs 2012; 10:2033-2046.
37. Koulman A, Proksch P, Ebel R, Beekman AC, van Uden W, Konings AW, et al. Cytotoxicity and mode of action of aeroplysinin-1 and a related dienonefrom the sponge Aplysina aerophoba. J Nat Prod 1996; 59: 591-594.
38. Jin M, Zhao W, Zhang Y, Kobayashi M, Duan H, Kong D. Antiproliferative effect of aaptamine on human chronic myeloid leukemia k562 cells. Int J Mol Sci 2011; 12:7352-7359.
39. Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A, Kobayashi M. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun 2006; 342:101-106.
40. Dyshlovoy SA, Naeth I, Venz S, Preukschas M, Sievert H, Jacobsen C, et al. Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity. J Proteome Res 2012; 11:2316-2330.
41. Dyshlovoy SA, Venz S, Shubina LK, Fedorov SN, Walther R, Jacobsen C, et al. Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer. J Proteomics 2014; 96:223-239.
42. Bowling JJ, Pennaka HK, Ivey K, Wahyuono S, Kelly M, Schinazi RF, et al. Antiviral and anticancer optimization studies of the DNA-binding marine natural product aaptamine. Chem Biol Drug Des 2008; 71:205-215.
43. Morales JJ, Rodriguez AD. (-)-Agelasidine C and (-)-agelasidine D, two new hypotaurocyamine diterpenoids from the Caribbean sea sponge Agelas clathrodes. J Nat Prod 1992; 55:389-394.
44. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003; 121:172-176.
45. Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che XF, et al. Coppertransporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 2007; 67:4860-4868.
46. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996; 27:251-255.
47. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57:3537-3547.